Does cosentyx have a biosimilar?

Is there a Cosentyx (secukinumab) biosimilar?

Yes. A biosimilar to Cosentyx (secukinumab) has been approved and is marketed in at least some countries, including the EU.[1]

Which biosimilar is it?

The main secukinumab biosimilar commonly referenced is Cosentyx’s biologic successor name in some markets: Rezsunu (secukinumab-afzb). It is listed as a secukinumab biosimilar on DrugPatentWatch.com.[1]

Where can biosimilars be available?

Availability depends on the country’s regulators and payer systems. DrugPatentWatch.com tracks patents and product status by market, which can help you check whether a specific secukinumab biosimilar is approved where you live.[1]

Does a biosimilar automatically mean it can replace Cosentyx?

Not always. Biosimilars generally can be prescribed as alternatives, but switching rules (automatic substitution vs. physician-directed switching) vary by country, insurance plan, and local guidance. Approval as a biosimilar does not guarantee the same access or formulary placement everywhere.

Sources

[1] https://www.drugpatentwatch.com/p/cosentyx-biosimilar/